Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares were down 7% during trading on Wednesday . The stock traded as low as $17.46 and last traded at $17.98. Approximately 1,433,298 shares were traded during mid-day trading, an increase of 38% from the average daily volume of 1,039,810 shares. The stock had previously closed at $19.33.
Analysts Set New Price Targets
Several research analysts have issued reports on the company. Oppenheimer reiterated an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday, September 20th. Finally, Maxim Group raised their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $22.60.
Read Our Latest Report on CAPR
Capricor Therapeutics Stock Down 10.5 %
The stock has a 50-day moving average of $6.63 and a 200 day moving average of $5.84. The company has a market capitalization of $553.56 million, a PE ratio of -20.26 and a beta of 4.01.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. Equities analysts forecast that Capricor Therapeutics Inc will post -1.14 EPS for the current fiscal year.
Insider Buying and Selling at Capricor Therapeutics
In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the company's stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares of the company's stock, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 12.00% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Capricor Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. BNP Paribas Financial Markets purchased a new position in shares of Capricor Therapeutics in the first quarter worth about $40,000. SG Americas Securities LLC purchased a new position in Capricor Therapeutics in the 3rd quarter valued at approximately $133,000. Main Street Financial Solutions LLC raised its holdings in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock valued at $131,000 after acquiring an additional 7,500 shares during the period. Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics during the second quarter worth $147,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after acquiring an additional 9,040 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
